Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02201550

Enrollment

Registered

2014-07-28

Start date

2013-02-28

Completion date

2014-04-30

Last updated

2014-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes. The hypotheses are: * Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood * Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood * Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * BMI \> 27 kg/m2 * Planed start of treatment with liraglutide * Age \> 18 years

Exclusion criteria

* Infection or active inflammatory disorder * Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids) * Smoking * Alcohol consumption \> 14 beverages/week * Former bariatric surgery

Design outcomes

Primary

Measure	Time frame
Change in number of specific immune cells in blood detected by flow cytometry	Before and 12 weeks after initiation of liraglutide treatment

Countries

Denmark

Outcome results